Navigation Links
Jennerex Appoints Lara Longpre to Chief Operating Officer
Date:8/25/2010

SAN FRANCISCO, Aug. 25 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced the appointment of Lara Longpre to the position of chief operating officer. Ms. Longpre will be responsible for the development of the company's lead product, JX-594, as well as Jennerex's other product candidates in development and will lead the clinical operations and research, manufacturing, regulatory and quality functions. Ms. Longpre has served as a consultant to Jennerex since 2009.

"Lara's extensive experience in developing therapeutics will make her a key member of our executive management team," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "Her systematic and meticulous approach to operations, combined with her demonstrated leadership ability, make Lara the ideal person to direct the development of JX-594 as we move toward late stage clinical trials in advanced liver cancer."

Ms. Longpre brings to Jennerex over 17 years of broad clinical research, operations, and leadership expertise in all stages of clinical development.  Prior to Jennerex, Ms. Longpre held the position of  senior vice president, clinical and corporate affairs at MedGenesis Therapeutix and held senior positions at PRA International, a global CRO, including vice president of proposals and contracts, vice president of quality and process management, director of global regulatory affairs, and director of operations. She has directly managed several pivotal Phase 3 trials, and has specific expertise in project management, clinical operations, and quality management systems, including achieving ISO 9001:2000 registration and ensuring Sarbanes-Oxley compliance while at an international CRO. Ms. Longpre holds an M.Sc. in Medical Science from Harvard Medical School, an MBA from Queens University, and B.A. from Cornell University.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells.  Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Pusan, South Korea.  For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. West Pharmaceutical Services, Inc. Appoints New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... , June 9, 2017 More than 400 ... effort to help spread lessons learned from clinical research ... Diabetes Federation (IDF) and Eli Lilly and Company (NYSE: ... second phase of the Bringing Research in Diabetes to ... commitment to helping people with diabetes effectively manage their ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an eastern ... access to asset protection and financial planning services, is teaming up with the ... lives of children with cancer and other chronic diseases. , The For A ...
(Date:6/22/2017)... IN (PRWEB) , ... June 22, 2017 , ... ... benefits advisory organization, is pleased to welcome Whipple & Company as its newest ... the clear purpose of balancing their clients’ risk while tailoring optimized benefit packages ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many physicians ... available that integrate basic science with clinical practice. Now, however, a timely review has ... clinicians with insight into the etiology of NeuP and educating preclinical scientists on its ...
(Date:6/22/2017)... ... 22, 2017 , ... A June 12 article in The Star ... apparent lack of oral hygiene by an aged parent who had recently suffered a ... a number of steps, including scheduling a dentist visit. Northridge Dental Works, a Los ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... a Texas-based health system, will present how predictive analytics drive reimbursement optimization, with ... meeting in Orlando, June 25-28. , “The traditional approach to denied and ...
Breaking Medicine News(10 mins):